Systemic sclerosis (scleroderma) trials in China

In China 64 Also abroad 213

64 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Early phase 1Not yet taking people in China
Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.
Where
Wuhan
Age
18 years and over
People
24
Run by
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT06982534
Phase 1Taking people
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Where
Beijing
Age
18 years to 65 years
People
44
Run by
Beijing GoBroad Hospital
See details and how to joinNCT06980597
Phase 1Not yet taking people in China
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
Where
Changzhou
Age
18 years and over
People
18
Run by
Changzhou No.2 People's Hospital
See details and how to joinNCT06978738
Early phase 1Not yet taking people in China
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Where
Suzhou
Age
18 years and over
People
15
Run by
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT06970951
No phaseTaking people
An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
Where
Changsha
Age
18 years and over
People
18
Run by
The First Affiliated Hospital of University of Science and Technology of China
See details and how to joinNCT06503224
Phase 2Taking people
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Where
Beijing
Age
18 years to 65 years
People
50
Run by
Peking University People's Hospital
See details and how to joinNCT06794008
No phaseNot yet taking people in China
Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases
Where
Hefei
Age
18 years to 70 years
People
18
Run by
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT06871644
Phase 2Taking people
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
Where
Hangzhou, Huzhou, Jiaxing, Ningbo, Shanghai, Wenzhou, Yangzhou
Age
18 years to 70 years
People
38
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06375005
Phase 2Taking people
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
Where
Beijing, Chengdu, Jinan, Wuhan
Age
18 years to 75 years
People
30
Run by
Changchun GeneScience Pharmaceutical Co., Ltd.
See details and how to joinNCT06189495
No phaseEnrolling by invitation
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
Where
Shanghai
Age
18 years to 65 years
People
15
Run by
Bioray Laboratories
See details and how to joinNCT05859997
Phase 1Taking people
Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis
Where
Shanghai
Age
18 years to 65 years
People
6
Run by
Liangjing Lu
See details and how to joinNCT06414135
Early phase 1Not yet taking people in China
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
Where
Wenzhou
Age
18 years to 65 years
People
9
Run by
First Affiliated Hospital of Wenzhou Medical University
See details and how to joinNCT06420154
No phaseTaking people
Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
Where
Beijing, Changsha, Chongqing, Hangzhou, Nanjing, Shenzhen
Age
Up to 18 years
People
20,000
Run by
Peking Union Medical College Hospital
See details and how to joinNCT06417502
Phase 1/2Taking people
RY_SW01 Cell Injection Therapy in Systemic Sclerosis
Where
Nanjing
Age
18 years to 65 years
People
81
Run by
Jiangsu Renocell Biotech Company
See details and how to joinNCT06058091